In a recent study, researchers found a new cancer vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
They are ready to try a new cancer vaccine in humans following the successful outcome of their preclinical studies.
They hope this vaccine could be used to treat blood cancers, such as myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma, and pediatric leukemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma.
The research was conducted by a team at The Translational Research Institute.
The new vaccine is comprised of human antibodies fused with tumor-specific protein, and the team is investigating its capacity to target human cells while activating the memory of the tumor cells.
The team says the vaccine offers several key advantages over existing cancer vaccines, which have already shown promise in early clinical trials.
First, it can be produced as an ‘off the shelf’ clinical-grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines.
Secondly, this prototype vaccine targets the key tumor cells required for the initiation of tumor-specific immune responses, thereby maximizing the potential effectiveness of treatment, while minimizing potential side effects.
The researchers hope their continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future.
One author of the study is Associate Professor Kristen Radford.
The study is published in Clinical and Translational Immunology.
Copyright © 2020 Knowridge Science Report. All rights reserved.
